Advanced Clinical Trial Workshops in China (ACT China)

Clinical trials play a vital role in improving outcomes for cancer patients. In 2011, the combined forces of the Chinese Society of Clinical Oncology (CSCO) and STO, with faculty support from the U.S. Food and Drug Administration (FDA)European Medicine Agency (EMA), and American Society of Clinical Oncology (ASCO), created and conducted Advanced Clinical Trial Workshops in China (ACT China), developed a clinical trial curriculum covering ethics, preclinical studies, clinical trial design/conduct, statistics, and regulatory considerations. During these meetings, a global faculty of experts addressed current issues and challenges in executing phase I, II, and III clinical trials, through a series of lectures, discussions, and workshops.

The curriculum was designed by an international steering committee of experts from CSCO, FDA, EMA and ASCO to help transform oncology research in China for the benefit of cancer patients in China and around the world.

Previous Programs 

ACT China I
Program PDF
Nov. 18-20,  2011
Rose Manor, Taicang (Shanghai)

ACT China II
Program PDF
Nov. 30 – Dec. 2, 2012
The Vanburgh Hotel, Guangzhou

ACT China III
Program PDF
Nov. 22 – 24, 2013
Hilton Baiyun Hotel, Guangzhou

ACT China IV
Program PDF
Nov. 21-23, 2014
Hilton Shenzhen Shekou Nanhai